ANGLE plc, a liquid biopsy company specializing in circulating tumor cell (CTC) diagnostic solutions, has announced the launch of its Portrait Flex CTC assay. The assay is conducted by ANGLE's Onc-ADaPT GCP-compliant laboratories and provides tailored analyses of CTCs. CTCs captured using ANGLE's Parsortix technology are enumerated and characterized using immunofluorescence staining for various markers. The assay has an analytical sensitivity of over 93% and an analytical specificity of over 95% for both epithelial and mesenchymal markers. Clinical samples from metastatic breast cancer patients showed that the assay could identify CTCs in 81% of patients, with 38.5% of CTC-positive patients having high HER2 levels. The launch of the Portrait Flex assay is part of ANGLE's strategy to develop a menu of imaging and molecular assays to support its pharma services business and product business for third-party customers.